

## Disclosures

### Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Amgen Inc.	Other - Academic Research Organization (ARO) Agreement - to Institution	Significant (>= \$5,000)	<a href="#">Prevention</a>
Avilar Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
GSK	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Intercept Pharmaceuticals Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Prevention</a>
Life Extension	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Lipigon Pharmaceuticals Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
MediMergent LLC	Stock	Significant (>= \$5,000)	<a href="#">Prevention</a>
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Rona Therapeutics, Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Wolters Kluwer	Other - Royalties	Significant (>= \$5,000)	<a href="#">Prevention</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
CVCT Scientific Program Planning Committee	Other - Scientific Program Planning Committee Member	None (\$0)	<a href="#">Prevention</a>
Novartis Pharmaceuticals	Other - National coordinator for VICTORION-2-PREVENT Phase 3 clinical trial	None (\$0)	<a href="#">Prevention</a>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

<sup>†</sup> Commercial Funding Source | <sup>‡</sup> Trial Name

## Agreement

### Certified Education Attestation

| Signed on 7/22/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement

| Signed on 7/22/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo

| Signed on 7/22/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.